172 related articles for article (PubMed ID: 19285661)
1. An integrated network-based mechanistic model for tumor growth dynamics under drug administration.
Ribeiro D; Pinto JM
Comput Biol Med; 2009 Apr; 39(4):368-84. PubMed ID: 19285661
[TBL] [Abstract][Full Text] [Related]
2. Chemotherapy may be delivered based on an integrated view of tumour dynamics.
Ribba B; You B; Tod M; Girard P; Tranchand B; Trillet-Lenoir V; Freyer G
IET Syst Biol; 2009 May; 3(3):180-90. PubMed ID: 19449978
[TBL] [Abstract][Full Text] [Related]
3. Modeling multi-drug chemotherapy: tailoring treatment to individuals.
Gardner SN
J Theor Biol; 2002 Jan; 214(2):181-207. PubMed ID: 11812172
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics/pharmacodynamics in drug development: an industrial perspective.
Chaikin P; Rhodes GR; Bruno R; Rohatagi S; Natarajan C
J Clin Pharmacol; 2000 Dec; 40(12 Pt 2):1428-38. PubMed ID: 11185663
[TBL] [Abstract][Full Text] [Related]
5. Modelling and simulation of chemotherapy of haematological and gynaecological cancers.
Nani FK; Oğuztöreli MN
IMA J Math Appl Med Biol; 1999 Mar; 16(1):39-91. PubMed ID: 10335600
[TBL] [Abstract][Full Text] [Related]
6. A qualitative approach to cell growth modeling and simulation for cancer chemotherapy.
Gaglio S; Giacomini M; Nicolini C; Ruggiero C
IEEE Trans Biomed Eng; 1991 Apr; 38(4):386-9. PubMed ID: 1855803
[TBL] [Abstract][Full Text] [Related]
7. A microenvironment based model of antimitotic therapy of Gompertzian tumor growth.
Kozusko F; Bourdeau M; Bajzer Z; Dingli D
Bull Math Biol; 2007 Jul; 69(5):1691-708. PubMed ID: 17577604
[TBL] [Abstract][Full Text] [Related]
8. Mathematical modeling of cancer progression and response to chemotherapy.
Sanga S; Sinek JP; Frieboes HB; Ferrari M; Fruehauf JP; Cristini V
Expert Rev Anticancer Ther; 2006 Oct; 6(10):1361-76. PubMed ID: 17069522
[TBL] [Abstract][Full Text] [Related]
9. Kinetic computational alanine scanning: application to p53 oligomerization.
Chong LT; Swope WC; Pitera JW; Pande VS
J Mol Biol; 2006 Mar; 357(3):1039-49. PubMed ID: 16457841
[TBL] [Abstract][Full Text] [Related]
10. A multiscale mathematical model of avascular tumor growth to investigate the therapeutic benefit of anti-invasive agents.
Ribba B; Saut O; Colin T; Bresch D; Grenier E; Boissel JP
J Theor Biol; 2006 Dec; 243(4):532-41. PubMed ID: 16930628
[TBL] [Abstract][Full Text] [Related]
11. Mixed immunotherapy and chemotherapy of tumors: feedback design and model updating schemes.
Chareyron S; Alamir M
J Theor Biol; 2009 Jun; 258(3):444-54. PubMed ID: 18655792
[TBL] [Abstract][Full Text] [Related]
12. Optimal controls for a model with pharmacokinetics maximizing bone marrow in cancer chemotherapy.
Ledzewicz U; Schättler H
Math Biosci; 2007 Apr; 206(2):320-42. PubMed ID: 16197967
[TBL] [Abstract][Full Text] [Related]
13. Robustness of the p53 network and biological hackers.
Dartnell L; Simeonidis E; Hubank M; Tsoka S; Bogle ID; Papageorgiou LG
FEBS Lett; 2005 Jun; 579(14):3037-42. PubMed ID: 15896791
[TBL] [Abstract][Full Text] [Related]
14. Modeling the interaction between the N-terminal domain of the tumor suppressor p53 and azurin.
Taranta M; Bizzarri AR; Cannistraro S
J Mol Recognit; 2009; 22(3):215-22. PubMed ID: 19140135
[TBL] [Abstract][Full Text] [Related]
15. TGI-Simulator: a visual tool to support the preclinical phase of the drug discovery process by assessing in silico the effect of an anticancer drug.
Terranova N; Magni P
Comput Methods Programs Biomed; 2012 Feb; 105(2):162-74. PubMed ID: 22005012
[TBL] [Abstract][Full Text] [Related]
16. Chemotherapy for tumors: an analysis of the dynamics and a study of quadratic and linear optimal controls.
de Pillis LG; Gu W; Fister KR; Head T; Maples K; Murugan A; Neal T; Yoshida K
Math Biosci; 2007 Sep; 209(1):292-315. PubMed ID: 17306310
[TBL] [Abstract][Full Text] [Related]
17. Modelling in tumour biology part 1: modelling concepts and structures.
Rew DA
Eur J Surg Oncol; 2000 Feb; 26(1):87-94. PubMed ID: 10718187
[TBL] [Abstract][Full Text] [Related]
18. Modeling oxaliplatin drug delivery to circadian rhythms in drug metabolism and host tolerance.
Clairambault J
Adv Drug Deliv Rev; 2007 Aug; 59(9-10):1054-68. PubMed ID: 17707544
[TBL] [Abstract][Full Text] [Related]
19. Towards whole-organ modelling of tumour growth.
Alarcón T; Byrne HM; Maini PK
Prog Biophys Mol Biol; 2004; 85(2-3):451-72. PubMed ID: 15142757
[TBL] [Abstract][Full Text] [Related]
20. PK/PD modelling and simulations: utility in drug development.
Rajman I
Drug Discov Today; 2008 Apr; 13(7-8):341-6. PubMed ID: 18405847
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
